A PROPRIETARY APPROACH TO REDUCE BURDEN OF CURRENT THERAPIES FOR PATIENTS WITH RETINAL DISEASE
Our Vision
Imagine safer and more convenient treatments for neovascular and degenerative retinal diseases that do not compromise on efficacy.
At Optigo Bio, we imagined this for you and are making it a reality.
A Novel Therapeutic
Leveraging our platform, we are developing a novel treatment which aims to counter the effects of neovascular retinal diseases, designed to be delivered once a year.
With all the benefits of anti-angiogenic injections that prevent further Macular Degeneration and restore lost vision, our therapy offers unrivaled innovation.
How we're doing it
We have developed proprietary precision targeted protein domains that bind to various components of the vitreous gel. These can be fused to existing and future retinal biologics, creating bi-specific molecules that anchor the biologic to the vitreous gel with the aim of significantly extending half-life and duration of action without impacting efficacy.
Our aim is to address one of the most pressing unmet needs of intravitreal injections, which is the burden of frequent injections on patients, physicians, and payers.
An intravitreal sustained release platform that harnesses components of the vitreous gel to prolong duration of existing and future intravitreal drugs used to treat retinal diseases, such as Geographic Atrophy (GA).
Vitreous Anchor Platform
Our Company
Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases, many of which are currently treated by monthly or bimonthly injections of drugs into the eye(s) by a retina specialist.
We believe that by reducing the frequency at which each dose of drug is delivered, we will reduce the inconvenience, discomfort, risk and expense of existing treatments. In doing so, we hope to reduce the number of patients dropping out of their treatment cycles or having to skip doses due to inconvenient timing.
Optigo Bio's pipeline therapy for retinal neovascular diseases and platform technology to enhance durability of approved and future drugs to treat Geographic Atrophy aim to prevent vision loss from these blinding retinal diseases with far fewer injections into the eye.
Our logo was inspired directly by the novelty of our technology.
The retina is the core of our technology, as depicted by the circle.
The 12 segments represent each monthly injection of medication into the eye.
Our mission is to reduce the frequency of risky, expensive, and burdensome injections to twice per year.
A convenient and effective solution for lifetime better vision.
Meet Our Purpose-Driven and Seasoned Team
